Immune Reveal Benefits
The Immune Reveal's comprehensive screening will enable a broader implementation of proactive care
Decoding and harnessing the power of the human immune system is one of the great frontiers of biomedicine … Developing AI models of the human immune system represent the next revolution in biomedicine.”
Eric Schmidt | former CEO, Google; W. Koff, Human Immunome Project; P. Doherty, Nobel laureate.
"The human immune system is an astonishing diagnostic system, continuously adapting itself to detect any signal of disease in the body. Essentially, the state of the immune system tells a story about virtually everything affecting a person’s health. It may sound like science fiction, but what if we could “read” this story? Our scientific understanding of human health would be fundamentally advanced. And more importantly, this would provide a foundation for a new generation of precise medical diagnostic and treatment options“
Peter Lee, President Microsoft Research
“By breaking the code of the immune system, we believe we will be able to determine your state of health and your response to therapies in essentially every human disease.”
J. Epstein, MD, Chief Scientific Officer, Penn Medicine
Immune Reveal simultaneous scans for many diseases making regular screening viable in terms of time and cost
The immune system has higher accuracy than many of today’s confirmatory tests and has inherently a very low false-positive rate
The immune system excels at early disease detection before symptoms when treatment is most effective
Easy-to-use point-of-care (POC) analyzer can be used by healthcare professionals in all care settings
3M tape technology enables a multi-disease test cartridge to be available for less than $20
Honeywell micro-fluidic technology enables miniaturization resulting in an countertop instrument less than a foot wide
.png)
.png)
.png)
.png)
The founders have started two previous point-of-care diagnostic companies (IPO (NASDAQ) for one and the other was acquired leading to $1B/yr product line). They also started a financial services AI company enabling complex financial services for JPMorgan, Citigroup & Merrill Lynch.
Technology partners include Honeywell and the Battelle Institute, the world’s largest independent R&D organization.
Immune IQ has relationships with both Johns Hopkins and Massachusetts General Hospital.
Battelle's support of ImmuneIQ extends to facilitating app-based menu expansion, ensuring the platform remains dynamic and adaptable to evolving healthcare needs.
Battelle's network intelligence capabilities can optimize data transmission and processing, enhancing the efficiency of disease identification algorithms.
Through collaboration on integrated circuits, ImmuneIQ benefits from cutting-edge hardware solutions that maximize the performance of point-of-care analyzers.
By incorporating Battelle's expertise in developing instrument families, ImmuneIQ can streamline production and ensure consistency across their diagnostic systems.
Battelle's involvement in machine learning initiatives empowers ImmuneIQ in refining algorithms and improving the accuracy and scope of disease detection.
Lastly, by leveraging Battelle's clinical units, ImmuneIQ gains access to diverse testing environments for validating technology in real-world healthcare settings.
Instrument Status
Disposable Test Cards
Regulatory
Our team comprises seasoned industry veterans driving innovation, manufacturing, and technological advancements to revolutionize healthcare diagnostics.
Previously founded two other point-of-care blood testing companies, one of which completed a successful IPO on NASDAQ. The second was acquired by a large diagnostic company and the base technology is responsible for over $1B/yr in sales. Founded a company which led the early adoption of AI for wealth management, restricted stock, and retirement planning (JPMorgan, Citigroup and Merrill Lynch).
Dr. Fackler, in Critical Care Medicine at Johns Hopkins Hospital, spearheads advancements in the rapidly growing field of artificial intelligence in medicine, pioneering transformative approaches and applications.
Recognized leader in machine-learning-based manufacturing of complex POC disposables. She was previously involved in two successful POC blood-testing startups, one purchased by J&J and the other, where she served as Vice-President of Manufacturing, went public on NASDAQ.
Dr. Adalja, a Senior Scholar at Johns Hopkins Center for Health Security, is a pivotal expert in infectious diseases, particularly renowned for his contributions to understanding and addressing COVID-19, guiding responses and empowering stakeholders amid unprecedented challenges.
Michael is a prominent leader in the development of complex POC instruments. He has over 25 years of IVD and medical device product development, operations, and manufacturing experience. He has been led teams as COO and CTO in the development of hundreds of medical, IVD, and consumer-centric products in a variety of roles.
Dr. Parikh, extensively published and a sought-after speaker on Long-COVID, co-founds the Parikh Institute of Research, pioneering investigations in allergies, asthma, and immunology trials, boasting affiliations with Albert Einstein College of Medicine, Cleveland Clinic, and NYU Grossman School of Medicine.
International finance leader with proven ability to build and position companies for long-term growth/profitability. Public company, private equity, family company, start-up and acquisition/divestiture experience across multiple industries, geographies, and scale of businesses. Expertise in development and implementation of strategic business.
Dr. Jones, founder and director of Rocky Mountain Allergy at Tanner Clinic in Layton, Utah, and Immunity Group Australia in Sydney, exemplifies leadership and expertise in the field of allergy and immunology on a global scale.
